Comparative Pharmacology
Head-to-head clinical analysis: AVANDIA versus BYDUREON BCISE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDIA versus BYDUREON BCISE.
AVANDIA vs BYDUREON BCISE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
BYDUREON BCISE (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
Initial dose 4 mg orally once daily; may increase to 8 mg once daily or 4 mg twice daily if inadequate glycemic control after 8-12 weeks. Maximum dose 8 mg/day.
Subcutaneous injection, 2 mg once weekly.
None Documented
None Documented
3-4 hours (terminal elimination half-life). No clinically significant accumulation with once-daily dosing.
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration, but the extended-release formulation provides prolonged exposure over 2 weeks via continuous release from microspheres.
Primarily hepatic metabolism via CYP2C8, with minimal renal excretion of unchanged drug (<1%). Approximately 64% of the dose is excreted in urine as metabolites and 23% in feces as metabolites.
Excreted primarily via renal degradation; no significant biliary or fecal excretion. Approximately 70% of the dose is eliminated as intact exenatide via glomerular filtration and proteolytic catabolism.
Category C
Category C
Antidiabetic
Antidiabetic